In-vitro activities of temafloxacin, tosufloxacin (A-61827) and five other fluoroquinolone agents.
about
Temafloxacin pharmacokinetics in subjects with normal and impaired renal functionEfficacy and ocular penetration of sparfloxacin in experimental streptococcal endophthalmitisComparative in vitro activity of WIN 57273, a new fluoroquinolone antimicrobial agentIn vitro activities of sparfloxacin, tosufloxacin, ciprofloxacin, and fleroxacin.In vitro activity of tosufloxacin (A-61827; T-3262) against selected genital pathogensComparative in vitro activities of several new fluoroquinolones and beta-lactam antimicrobial agents against community isolates of Streptococcus pneumoniae.Current perspectives on glycopeptide resistance.In vitro activity of temafloxacin compared with those of other agents against 100 clinical isolates of Neisseria gonorrhoeae.Comparative activity of ciprofloxacin, ofloxacin, sparfloxacin, temafloxacin, CI-960, CI-990, and WIN 57273 against anaerobic bacteriaEfficacy and safety of temafloxacin versus those of amoxicillin in hospitalized adults with community-acquired pneumoniaSusceptibilities of penicillin-susceptible and -resistant strains of Streptococcus pneumoniae to RP 59500, vancomycin, erythromycin, PD 131628, sparfloxacin, temafloxacin, win 57273, ofloxacin, and ciprofloxacin.Susceptibility of enterococci and epidemiology of enterococcal infection in the 1980sActivity of temafloxacin against respiratory pathogens.Pharmacokinetics of temafloxacin in humans after single oral doses.Activity of new quinolones against ciprofloxacin-resistant staphylococciSpecies identification and antibiotic susceptibility testing of enterococci isolated from hospitalized patientsTemafloxacin disk potency and tentative interpretive criteria for susceptibility testsTopical 0.3% ciprofloxacin, norfloxacin, and ofloxacin in treatment of bacterial keratitis: a new method for comparative evaluation of ocular drug penetration.A review of the antimicrobial activity of the fluoroquinolones.Differing activities of quinolones against ciprofloxacin-susceptible and ciprofloxacin-resistant, methicillin-resistant Staphylococcus aureus.New quinolones and gram-positive bacteria.
P2860
Q24644483-CD5B412C-DC47-4DAA-B9B3-30D8835E8964Q28263381-2DDE6595-82A8-409C-ACC2-1EB479063105Q28335923-93CAA831-755E-411C-AD24-739C66F64061Q34601561-ED43F86C-CAF2-4356-85B0-B7ADB88B4F21Q34626011-6D333EA6-FCB1-442C-AB3B-9D3B336CFD69Q35250729-F7B7BF30-4A1F-4F7F-BCE1-9849A371D8DFQ35368590-3A4A83D8-7225-4CCF-9F06-28DAD06FED87Q35836677-20C2A945-2ECF-4383-8FDE-9B9CBBD0511DQ35836848-0CEE69B0-95CD-4A7B-824C-D2C07ECC2169Q35846059-78B83859-32DB-4217-8DD1-18257BE7FAE3Q35846320-0E8BA248-C455-4EE1-8FB9-19B37F470CB4Q36473436-2971A2E0-8E99-4BE5-874B-53DF6E1C8B40Q36753020-0EA92AA8-562C-4A3E-8FFF-528CA01A4AC1Q36753040-9F6F649E-EC01-4FD1-AAF3-0BBA9CE41BD9Q36754643-59A2073C-47C8-4A3E-B1AC-5FCD1A02A32FQ36755140-BD72758B-EC5C-46AA-9170-493ACDB2C2ECQ37164749-8DF4A078-3758-42CE-9A8E-EB9ACBF0986FQ37313306-63096B5A-F0FD-46F3-8A5A-309BFB1AAC11Q37834318-323964B1-0B6E-4F38-8734-5734EFC4E617Q40085890-364B5844-1BF2-4F61-ABF5-16630D082D52Q40284884-2B13990C-1D00-4B76-AA63-AA2C99EC0B62
P2860
In-vitro activities of temafloxacin, tosufloxacin (A-61827) and five other fluoroquinolone agents.
description
1989 nî lūn-bûn
@nan
1989年の論文
@ja
1989年学术文章
@wuu
1989年学术文章
@zh-cn
1989年学术文章
@zh-hans
1989年学术文章
@zh-my
1989年学术文章
@zh-sg
1989年學術文章
@yue
1989年學術文章
@zh
1989年學術文章
@zh-hant
name
In-vitro activities of temaflo ...... other fluoroquinolone agents.
@en
In-vitro activities of temaflo ...... other fluoroquinolone agents.
@nl
type
label
In-vitro activities of temaflo ...... other fluoroquinolone agents.
@en
In-vitro activities of temaflo ...... other fluoroquinolone agents.
@nl
prefLabel
In-vitro activities of temaflo ...... other fluoroquinolone agents.
@en
In-vitro activities of temaflo ...... other fluoroquinolone agents.
@nl
P356
P1476
In-vitro activities of temaflo ...... other fluoroquinolone agents.
@en
P2093
P304
P356
10.1093/JAC/23.4.527
P407
P577
1989-04-01T00:00:00Z